John Longshore is the Head of Scientific Affairs for Global Oncology Diagnostics at AstraZeneca. The Scientific Affairs team is accountable for the development and execution of global scientific strategy for AstraZeneca oncology diagnostic solutions worldwide. This includes maximizing global biomarker adoption, facilitating the development of local testing solutions, generating clinical evidence, and leading medical education for the laboratory community.
He works across the organization, often with colleagues in Global Diagnostics, Medical Affairs and Policy, to support the identification of key gaps and solutions for improved access to biomarker testing. The goal is to ensure that all patients have access to high-quality and timely biomarker testing.
Prior to joining AstraZeneca, John served for 20 years as the Director of Molecular Pathology for Carolinas Pathology Group. His job included being the Medical Director for the Molecular Pathology Laboratory for Atrium Health, a comprehensive molecular laboratory providing testing services in genetics, microbiology, virology, and oncology to support a 50+ hospital integrated health network in the Southeastern US.
Dr. Longshore is a diplomate of the American Board of Medical Genetics and Genomics and is an active member of the ACMG, ASHG, ESHG, AMP, IASLC, ESMO, and ASCO. His focal area of academic interest is the use of molecular markers in oncology to enable patient access to targeted therapies.
Updated: November 2021